Keren Sturtz
About
Keren Sturtz is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Keren Sturtz has authored 18 papers receiving a total of 971 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cancer Research, 8 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Keren Sturtz's work include Breast Cancer Treatment Studies (10 papers), Estrogen and related hormone effects (7 papers) and Advanced Breast Cancer Therapies (5 papers). Keren Sturtz is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), Estrogen and related hormone effects (7 papers) and Advanced Breast Cancer Therapies (5 papers). Keren Sturtz collaborates with scholars based in United States, Canada and Austria. Keren Sturtz's co-authors include J. Thaddeus Beck, Antonio C. Wolff, Kate Whelan, Clifford A. Hudis, Julie R. Gralow, Wendy R. Parulekar, S. Rubin, Nicholas J. Robert, Kathleen I. Pritchard and Hyman B. Muss and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
Keren Sturtz
18 papers receiving 948 citations
Hit Papers
Peers
Keren Sturtz
Fernando Lara-Medina Mexico
AS Coates Switzerland
J.P. Lobelle Belgium
Álvaro Rodríguez-Lescure Spain
Polly Niravath United States
Yavuz Özışık Türkiye
Marit Holmqvist Sweden
J Wolter United States
K.I. Pritchard Canada
Anne Irene Hagen Norway
Citations per year, relative to Keren Sturtz Keren Sturtz (= 1×)
peers
Fernando Lara-Medina
Countries citing papers authored by Keren Sturtz
Since
Specialization
Citations
This map shows the geographic impact of Keren Sturtz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keren Sturtz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keren Sturtz more than expected).
Fields of papers citing papers by Keren Sturtz
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Keren Sturtz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keren Sturtz. The network helps show where Keren Sturtz may publish in the future.
Co-authorship network of co-authors of Keren Sturtz
This figure shows the co-authorship network connecting the top 25 collaborators of Keren Sturtz. A scholar is included among the top collaborators of Keren Sturtz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keren Sturtz. Keren Sturtz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Beck, J. Thaddeus, Dale R. Shepard, Olivier Dumas, et al.. (2024). A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3180–TPS3180.
2.
Beck, J. Thaddeus, Meredith McKean, Shirish M. Gadgeel, et al.. (2023). A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.. Journal of Clinical Oncology. 41(16_suppl). TPS3164–TPS3164.
3.
Wagner, Lynne I., Janet A. Tooze, Daniel L. Hall, et al.. (2021). Targeted eHealth Intervention to Reduce Breast Cancer Survivors’ Fear of Recurrence: Results From the FoRtitude Randomized Trial. JNCI Journal of the National Cancer Institute. 113(11). 1495–1505.
4.
Barton, Debra L., Jeff A. Sloan, Lynne T. Shuster, et al.. (2017). Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Supportive Care in Cancer. 26(2). 643–650.
5.
Bandos, Hanna, Joy Melnikow, Donna R. Rivera, et al.. (2017). Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. JNCI Journal of the National Cancer Institute. 110(2).
6.
Goss, Paul E., James N. Ingle, Kathleen I. Pritchard, et al.. (2016). Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine. 375(3). 209–219.
7.
Goss, Paul E., James N. Ingle, Kathleen I. Pritchard, et al.. (2016). A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.. Journal of Clinical Oncology. 34(18_suppl). LBA1–LBA1.
8.
Belani, Chandra P., Suzanne E. Dahlberg, Charles M. Rudin, et al.. (2016). Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive‐stage small cell lung cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E1508). Cancer. 122(15). 2371–2378.
9.
Berry, DA, Bhupender Singh, C. Cirrincione, et al.. (2016). Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance). Cancer Research. 76(4_Supplement). S2–5.
10.
Goss, Paul E., James N. Ingle, Kathleen I. Pritchard, et al.. (2016). A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.. Journal of Clinical Oncology. 34(15_suppl). LBA1–LBA1.
11.
Ganz, PA, TB Julian, J. P. Costantino, et al.. (2016). Abstract S6-04: Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. Cancer Research. 76(4_Supplement). S6–4.
12.
Evens, Andrew M., Fangxin Hong, Thomas M. Habermann, et al.. (2016). Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).. Journal of Clinical Oncology. 34(15_suppl). 7507–7507.
13.
Abraham, Jame, André Robidoux, Antoinette R. Tan, et al.. (2015). Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9. Breast Cancer Research and Treatment. 152(2). 399–405.
14.
Ganz, Patricia A., Reena S. Cecchini, Thomas B. Julian, et al.. (2015). Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. The Lancet. 387(10021). 857–865.
15.
Margolese, Richard G., Reena S. Cecchini, Thomas B. Julian, et al.. (2015). Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. The Lancet. 387(10021). 849–856.
16.
Margolese, Richard G., Reena S. Cecchini, Thomas B. Julian, et al.. (2015). Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.. Journal of Clinical Oncology. 33(15_suppl). LBA500–LBA500.
17.
Margolese, Richard G., Reena S. Cecchini, Thomas B. Julian, et al.. (2015). Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.. Journal of Clinical Oncology. 33(18_suppl). LBA500–LBA500.
18.
Park, Haeseong, Rui Qin, Thomas J. Smith, et al.. (2014). North Central Cancer Treatment Group N10C2 (Alliance). Menopause The Journal of The North American Menopause Society. 22(6). 627–632.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Fernando Lara-Medina Breakdown of academic impact, for papers by AS Coates Breakdown of academic impact, for papers by J.P. Lobelle Breakdown of academic impact, for papers by Álvaro Rodríguez-Lescure Breakdown of academic impact, for papers by Polly Niravath Breakdown of academic impact, for papers by Yavuz Özışık Breakdown of academic impact, for papers by Marit Holmqvist Breakdown of academic impact, for papers by J Wolter Breakdown of academic impact, for papers by K.I. Pritchard Breakdown of academic impact, for papers by Anne Irene Hagen